BRPI0707446A2 - composições e métodos para o tratamento de doença oftálmica - Google Patents

Info

Publication number

BRPI0707446A2

BRPI0707446A2 BRPI0707446-8A BRPI0707446A BRPI0707446A2 BR PI0707446 A2 BRPI0707446 A2 BR PI0707446A2 BR PI0707446 A BRPI0707446 A BR PI0707446A BR PI0707446 A2 BRPI0707446 A2 BR PI0707446A2

Authority

BR

Brazil

Prior art keywords

seq

azepanyl

amino

group

ethyl

Prior art date

2006-02-02

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 125
• 239000000203 mixture Substances 0.000 title claims abstract description 117
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 30
• 238000011282 treatment Methods 0.000 title claims abstract description 18
• 201000010099 disease Diseases 0.000 title abstract description 26
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract description 129
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract description 123
• 239000003112 inhibitor Substances 0.000 claims abstract description 105
• -1 heterocycle compound Chemical class 0.000 claims description 100
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 98
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 66
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 63
• 108020004459 Small interfering RNA Proteins 0.000 claims description 59
• 125000004432 carbon atom Chemical group C* 0.000 claims description 56
• 239000004055 small Interfering RNA Substances 0.000 claims description 56
• 230000000694 effects Effects 0.000 claims description 54
• 239000007943 implant Substances 0.000 claims description 54
• 125000001424 substituent group Chemical group 0.000 claims description 50
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 48
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 45
• 230000002207 retinal effect Effects 0.000 claims description 45
• 150000001875 compounds Chemical class 0.000 claims description 44
• 150000007523 nucleic acids Chemical group 0.000 claims description 44
• 125000003729 nucleotide group Chemical group 0.000 claims description 44
• 102000039446 nucleic acids Human genes 0.000 claims description 43
• 108020004707 nucleic acids Proteins 0.000 claims description 43
• 108091034117 Oligonucleotide Proteins 0.000 claims description 38
• 239000002773 nucleotide Substances 0.000 claims description 36
• 235000001014 amino acid Nutrition 0.000 claims description 34
• 230000014509 gene expression Effects 0.000 claims description 29
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
• 125000000623 heterocyclic group Chemical group 0.000 claims description 28
• 108091030071 RNAI Proteins 0.000 claims description 25
• 230000009368 gene silencing by RNA Effects 0.000 claims description 25
• 230000027455 binding Effects 0.000 claims description 24
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
• 108020004999 messenger RNA Proteins 0.000 claims description 22
• 125000002950 monocyclic group Chemical group 0.000 claims description 21
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 18
• 208000017442 Retinal disease Diseases 0.000 claims description 18
• 125000003118 aryl group Chemical group 0.000 claims description 18
• 229920001184 polypeptide Polymers 0.000 claims description 18
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
• 229910052760 oxygen Inorganic materials 0.000 claims description 15
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 14
• 239000004005 microsphere Substances 0.000 claims description 14
• 229910052757 nitrogen Inorganic materials 0.000 claims description 14
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
• 229910052717 sulfur Inorganic materials 0.000 claims description 13
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
• 230000002401 inhibitory effect Effects 0.000 claims description 12
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 12
• 241000124008 Mammalia Species 0.000 claims description 11
• 239000005557 antagonist Substances 0.000 claims description 11
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
• 150000003839 salts Chemical class 0.000 claims description 11
• 229910052799 carbon Inorganic materials 0.000 claims description 10
• 230000000295 complement effect Effects 0.000 claims description 10
• 125000006165 cyclic alkyl group Chemical group 0.000 claims description 10
• 238000009826 distribution Methods 0.000 claims description 10
• 239000012634 fragment Substances 0.000 claims description 10
• 125000001072 heteroaryl group Chemical group 0.000 claims description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
• 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims description 9
• 230000003834 intracellular effect Effects 0.000 claims description 9
• 125000003367 polycyclic group Chemical group 0.000 claims description 9
• 125000005156 substituted alkylene group Chemical group 0.000 claims description 9
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 8
• 125000000217 alkyl group Chemical group 0.000 claims description 8
• 239000007788 liquid Substances 0.000 claims description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
• 108010061299 CXCR4 Receptors Proteins 0.000 claims description 7
• 102000012000 CXCR4 Receptors Human genes 0.000 claims description 7
• 101710163270 Nuclease Proteins 0.000 claims description 7
• 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 7
• 239000003446 ligand Substances 0.000 claims description 7
• 238000006467 substitution reaction Methods 0.000 claims description 7
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
• 125000005017 substituted alkenyl group Chemical group 0.000 claims description 6
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
• 239000000539 dimer Substances 0.000 claims description 5
• 125000004426 substituted alkynyl group Chemical group 0.000 claims description 5
• 239000003981 vehicle Substances 0.000 claims description 5
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
• 125000004419 alkynylene group Chemical group 0.000 claims description 4
• 125000002619 bicyclic group Chemical group 0.000 claims description 4
• 239000013604 expression vector Substances 0.000 claims description 4
• 125000005842 heteroatom Chemical group 0.000 claims description 4
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
• 230000003287 optical effect Effects 0.000 claims description 4
• 229940002612 prodrug Drugs 0.000 claims description 4
• 239000000651 prodrug Substances 0.000 claims description 4
• 230000009467 reduction Effects 0.000 claims description 4
• 125000004450 alkenylene group Chemical group 0.000 claims description 3
• 125000003277 amino group Chemical group 0.000 claims description 3
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 3
• 150000003857 carboxamides Chemical class 0.000 claims description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
• 230000001413 cellular effect Effects 0.000 claims description 3
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 3
• 125000005843 halogen group Chemical group 0.000 claims description 3
• YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 3
• SDFYFIRUYZGZPG-XPWZEYHZSA-N (3s)-n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]piperidine-3-carboxamide Chemical compound O=C([C@@H]1CNCCC1)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCCCC1 SDFYFIRUYZGZPG-XPWZEYHZSA-N 0.000 claims description 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 2
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims description 2
• OTIAVLWNTIXJDO-UHFFFAOYSA-N 5-aminopentanamide Chemical compound NCCCCC(N)=O OTIAVLWNTIXJDO-UHFFFAOYSA-N 0.000 claims description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
• 101150020251 NR13 gene Proteins 0.000 claims description 2
• 108700026244 Open Reading Frames Proteins 0.000 claims description 2
• DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
• 125000003545 alkoxy group Chemical group 0.000 claims description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
• 125000003282 alkyl amino group Chemical group 0.000 claims description 2
• 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 2
• 125000002947 alkylene group Chemical group 0.000 claims description 2
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
• 125000004122 cyclic group Chemical group 0.000 claims description 2
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 2
• 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims description 2
• 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims description 2
• 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims description 2
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
• 125000001188 haloalkyl group Chemical group 0.000 claims description 2
• 150000002391 heterocyclic compounds Chemical class 0.000 claims description 2
• 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 2
• 230000002452 interceptive effect Effects 0.000 claims description 2
• OYINMNOEWYITSF-UHFFFAOYSA-N n-[2-[1-ethyl-3-[(4-piperidin-1-ylpyrimidin-2-yl)amino]piperidin-2-yl]ethyl]piperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCCC1N(CC)CCCC1NC(N=1)=NC=CC=1N1CCCCC1 OYINMNOEWYITSF-UHFFFAOYSA-N 0.000 claims description 2
• OWIVCJDVGKSZCY-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-(1,3-dihydroxypropan-2-yl)piperidin-2-yl]ethyl]piperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCCC1N(C(CO)CO)CCCC1NC(N=1)=NC=CC=1N1CCCCCC1 OWIVCJDVGKSZCY-UHFFFAOYSA-N 0.000 claims description 2
• WOXPRFMBRXGQGJ-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-(3-hydroxypropyl)piperidin-2-yl]ethyl]piperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCCC1N(CCCO)CCCC1NC(N=1)=NC=CC=1N1CCCCCC1 WOXPRFMBRXGQGJ-UHFFFAOYSA-N 0.000 claims description 2
• ZDPBLMOKKGUWQH-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-(thian-4-yl)piperidin-2-yl]ethyl]piperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCSCC1 ZDPBLMOKKGUWQH-UHFFFAOYSA-N 0.000 claims description 2
• BEDMOCAFSCVWGW-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-propan-2-ylpiperidin-2-yl]ethyl]piperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCCC1N(C(C)C)CCCC1NC(N=1)=NC=CC=1N1CCCCCC1 BEDMOCAFSCVWGW-UHFFFAOYSA-N 0.000 claims description 2
• 150000002829 nitrogen Chemical class 0.000 claims description 2
• 125000004043 oxo group Chemical group O=* 0.000 claims description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
• 229920006395 saturated elastomer Polymers 0.000 claims description 2
• 125000001183 hydrocarbyl group Chemical group 0.000 claims 7
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 3
• 150000002148 esters Chemical class 0.000 claims 2
• APQRNAUXFIHFMW-BSSNWTCHSA-N (3s)-n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpyrrolidin-2-yl]ethyl]piperidine-3-carboxamide Chemical compound O=C([C@@H]1CNCCC1)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCN1C1CCCCC1 APQRNAUXFIHFMW-BSSNWTCHSA-N 0.000 claims 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
• MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
• 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 1
• 108091028664 Ribonucleotide Proteins 0.000 claims 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
• FYYOLKFRSBAUGY-LEWJYISDSA-N n-[(2r,3s)-2-(3-aminopropyl)-1-cyclohexylpyrrolidin-3-yl]-4-(azepan-1-yl)pyrimidin-2-amine Chemical compound C([C@@H]([C@H]1CCCN)NC=2N=C(C=CN=2)N2CCCCCC2)CN1C1CCCCC1 FYYOLKFRSBAUGY-LEWJYISDSA-N 0.000 claims 1
• FYYOLKFRSBAUGY-UHFFFAOYSA-N n-[2-(3-aminopropyl)-1-cyclohexylpyrrolidin-3-yl]-4-(azepan-1-yl)pyrimidin-2-amine Chemical compound NCCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCN1C1CCCCC1 FYYOLKFRSBAUGY-UHFFFAOYSA-N 0.000 claims 1
• DQJBSVNHNLGMNF-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-(1,1-dioxothian-4-yl)piperidin-2-yl]ethyl]piperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCS(=O)(=O)CC1 DQJBSVNHNLGMNF-UHFFFAOYSA-N 0.000 claims 1
• VNEOBUHJYVLPCF-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-(oxan-4-yl)piperidin-2-yl]ethyl]piperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCOCC1 VNEOBUHJYVLPCF-UHFFFAOYSA-N 0.000 claims 1
• JLZJIEIBNPFFGX-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]-4-hydroxypiperidine-4-carboxamide Chemical compound N=1C=CC(N2CCCCCC2)=NC=1NC1CCCN(C2CCCCC2)C1CCNC(=O)C1(O)CCNCC1 JLZJIEIBNPFFGX-UHFFFAOYSA-N 0.000 claims 1
• PMQJRNHBTBEQND-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]morpholine-2-carboxamide Chemical compound C1NCCOC1C(=O)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCCCC1 PMQJRNHBTBEQND-UHFFFAOYSA-N 0.000 claims 1
• HQGRTAMXYWZZOR-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]piperidine-2-carboxamide Chemical compound C1CCCNC1C(=O)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCCCC1 HQGRTAMXYWZZOR-UHFFFAOYSA-N 0.000 claims 1
• 125000003386 piperidinyl group Chemical group 0.000 claims 1
• 229960002429 proline Drugs 0.000 claims 1
• 235000013930 proline Nutrition 0.000 claims 1
• 239000002336 ribonucleotide Substances 0.000 claims 1
• 125000002652 ribonucleotide group Chemical group 0.000 claims 1
• 208000030533 eye disease Diseases 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 87
• 210000001508 eye Anatomy 0.000 description 66
• CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 50
• 241000282414 Homo sapiens Species 0.000 description 33
• 150000001413 amino acids Chemical class 0.000 description 31
• 208000002780 macular degeneration Diseases 0.000 description 31
• 239000003814 drug Substances 0.000 description 30
• 229920000642 polymer Polymers 0.000 description 29
• 210000001519 tissue Anatomy 0.000 description 28
• 206010064930 age-related macular degeneration Diseases 0.000 description 26
• 238000012377 drug delivery Methods 0.000 description 26
• 230000001225 therapeutic effect Effects 0.000 description 26
• 108090000623 proteins and genes Proteins 0.000 description 23
• 102000019034 Chemokines Human genes 0.000 description 21
• 108010012236 Chemokines Proteins 0.000 description 21
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 21
• 230000001939 inductive effect Effects 0.000 description 21
• 239000002245 particle Substances 0.000 description 21
• 239000000463 material Substances 0.000 description 20
• 102000005962 receptors Human genes 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• 239000000243 solution Substances 0.000 description 17
• 235000018102 proteins Nutrition 0.000 description 16
• 102000004169 proteins and genes Human genes 0.000 description 16
• 229940079593 drug Drugs 0.000 description 15
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 14
• 206010012689 Diabetic retinopathy Diseases 0.000 description 14
• 239000000872 buffer Substances 0.000 description 14
• 239000003795 chemical substances by application Substances 0.000 description 14
• 229940124597 therapeutic agent Drugs 0.000 description 14
• 238000002347 injection Methods 0.000 description 13
• 239000007924 injection Substances 0.000 description 13
• 239000002299 complementary DNA Substances 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 11
• 208000001344 Macular Edema Diseases 0.000 description 11
• 229920001577 copolymer Polymers 0.000 description 11
• 239000011159 matrix material Substances 0.000 description 11
• 239000002609 medium Substances 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 239000003755 preservative agent Substances 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 239000002585 base Substances 0.000 description 10
• 229920002988 biodegradable polymer Polymers 0.000 description 10
• 239000004621 biodegradable polymer Substances 0.000 description 10
• 230000030833 cell death Effects 0.000 description 10
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 9
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 9
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 9
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 206010025415 Macular oedema Diseases 0.000 description 9
• 206010028980 Neoplasm Diseases 0.000 description 9
• 230000001154 acute effect Effects 0.000 description 9
• 201000010230 macular retinal edema Diseases 0.000 description 9
• 239000000816 peptidomimetic Substances 0.000 description 9
• 239000000049 pigment Substances 0.000 description 9
• 108020004414 DNA Proteins 0.000 description 8
• 208000010412 Glaucoma Diseases 0.000 description 8
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
• 206010046851 Uveitis Diseases 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 230000001965 increasing effect Effects 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 230000002335 preservative effect Effects 0.000 description 8
• 201000004569 Blindness Diseases 0.000 description 7
• 108091006027 G proteins Proteins 0.000 description 7
• 102000030782 GTP binding Human genes 0.000 description 7
• 108091000058 GTP-Binding Proteins 0.000 description 7
• 210000003161 choroid Anatomy 0.000 description 7
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 7
• 150000002430 hydrocarbons Chemical group 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 210000001525 retina Anatomy 0.000 description 7
• 230000004304 visual acuity Effects 0.000 description 7
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 210000000695 crystalline len Anatomy 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 210000000981 epithelium Anatomy 0.000 description 6
• 102000053523 human CXCR4 Human genes 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000008733 trauma Effects 0.000 description 6
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
• NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 5
• WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 5
• 150000001408 amides Chemical class 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 210000005252 bulbus oculi Anatomy 0.000 description 5
• 239000002975 chemoattractant Substances 0.000 description 5
• 230000007850 degeneration Effects 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 229920002674 hyaluronan Polymers 0.000 description 5
• 229940014041 hyaluronate Drugs 0.000 description 5
• 229960003160 hyaluronic acid Drugs 0.000 description 5
• 238000009396 hybridization Methods 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 210000000265 leukocyte Anatomy 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 210000001328 optic nerve Anatomy 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 230000035882 stress Effects 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• 231100000419 toxicity Toxicity 0.000 description 5
• 230000001988 toxicity Effects 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 208000009137 Behcet syndrome Diseases 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 102000009410 Chemokine receptor Human genes 0.000 description 4
• 108050000299 Chemokine receptor Proteins 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
• 206010029113 Neovascularisation Diseases 0.000 description 4
• 206010030113 Oedema Diseases 0.000 description 4
• 229920000954 Polyglycolide Polymers 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 208000029977 White Dot Syndromes Diseases 0.000 description 4
• 208000023564 acute macular neuroretinopathy Diseases 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000001857 anti-mycotic effect Effects 0.000 description 4
• 239000002543 antimycotic Substances 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• 230000003115 biocidal effect Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 230000004378 blood-retinal barrier Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000003570 cell viability assay Methods 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 230000035605 chemotaxis Effects 0.000 description 4
• 210000000795 conjunctiva Anatomy 0.000 description 4
• 201000011190 diabetic macular edema Diseases 0.000 description 4
• 238000009792 diffusion process Methods 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 230000003628 erosive effect Effects 0.000 description 4
• 239000000835 fiber Substances 0.000 description 4
• 238000013534 fluorescein angiography Methods 0.000 description 4
• 230000030279 gene silencing Effects 0.000 description 4
• QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 230000004410 intraocular pressure Effects 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 230000036542 oxidative stress Effects 0.000 description 4
• 229940056360 penicillin g Drugs 0.000 description 4
• 229920000747 poly(lactic acid) Polymers 0.000 description 4
• 229920000728 polyester Polymers 0.000 description 4
• 229920002451 polyvinyl alcohol Polymers 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 4
• 208000004644 retinal vein occlusion Diseases 0.000 description 4
• 159000000000 sodium salts Chemical class 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 229960002385 streptomycin sulfate Drugs 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 230000032258 transport Effects 0.000 description 4
• WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 3
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• MNBHKGYCLBUIBC-UFYCRDLUSA-N Arg-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MNBHKGYCLBUIBC-UFYCRDLUSA-N 0.000 description 3
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 3
• ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 3
• PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 108010008951 Chemokine CXCL12 Proteins 0.000 description 3
• 102000006573 Chemokine CXCL12 Human genes 0.000 description 3
• DVIHGGUODLILFN-GHCJXIJMSA-N Cys-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N DVIHGGUODLILFN-GHCJXIJMSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• UUTGYDAKPISJAO-JYJNAYRXSA-N Glu-Tyr-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 UUTGYDAKPISJAO-JYJNAYRXSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• TWYOYAKMLHWMOJ-ZPFDUUQYSA-N Ile-Leu-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O TWYOYAKMLHWMOJ-ZPFDUUQYSA-N 0.000 description 3
• 108010065920 Insulin Lispro Proteins 0.000 description 3
• JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
• ZJSXCIMWLPSTMG-HSCHXYMDSA-N Lys-Trp-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZJSXCIMWLPSTMG-HSCHXYMDSA-N 0.000 description 3
• DCHHUGLTVLJYKA-FXQIFTODSA-N Met-Asn-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O DCHHUGLTVLJYKA-FXQIFTODSA-N 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 208000010164 Multifocal Choroiditis Diseases 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 3
• 208000018262 Peripheral vascular disease Diseases 0.000 description 3
• 239000004372 Polyvinyl alcohol Substances 0.000 description 3
• 201000007737 Retinal degeneration Diseases 0.000 description 3
• 206010038848 Retinal detachment Diseases 0.000 description 3
• 206010038910 Retinitis Diseases 0.000 description 3
• NYQIZWROIMIQSL-VEVYYDQMSA-N Thr-Pro-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O NYQIZWROIMIQSL-VEVYYDQMSA-N 0.000 description 3
• 101710120037 Toxin CcdB Proteins 0.000 description 3
• 102000014384 Type C Phospholipases Human genes 0.000 description 3
• 108010079194 Type C Phospholipases Proteins 0.000 description 3
• SEFNTZYRPGBDCY-IHRRRGAJSA-N Tyr-Arg-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N)O SEFNTZYRPGBDCY-IHRRRGAJSA-N 0.000 description 3
• 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 3
• 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
• 229960003942 amphotericin b Drugs 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 210000002159 anterior chamber Anatomy 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• 108010062796 arginyllysine Proteins 0.000 description 3
• 108010093581 aspartyl-proline Proteins 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000004888 barrier function Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 210000004155 blood-retinal barrier Anatomy 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000003833 cell viability Effects 0.000 description 3
• 201000005667 central retinal vein occlusion Diseases 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000000562 conjugate Substances 0.000 description 3
• 210000004087 cornea Anatomy 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 108010060199 cysteinylproline Proteins 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 238000012226 gene silencing method Methods 0.000 description 3
• 150000004676 glycans Chemical class 0.000 description 3
• 230000003394 haemopoietic effect Effects 0.000 description 3
• 229920001519 homopolymer Polymers 0.000 description 3
• 238000002513 implantation Methods 0.000 description 3
• 210000000554 iris Anatomy 0.000 description 3
• 239000004310 lactic acid Substances 0.000 description 3
• 235000014655 lactic acid Nutrition 0.000 description 3
• JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
• 108010054155 lysyllysine Proteins 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 239000011859 microparticle Substances 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 229920001610 polycaprolactone Polymers 0.000 description 3
• 229920001282 polysaccharide Polymers 0.000 description 3
• 239000005017 polysaccharide Substances 0.000 description 3
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 3
• 230000004264 retinal detachment Effects 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 210000003786 sclera Anatomy 0.000 description 3
• 210000002536 stromal cell Anatomy 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 210000004127 vitreous body Anatomy 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
• VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
• 108020005345 3' Untranslated Regions Proteins 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 2
• 102100027211 Albumin Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• LMPKCSXZJSXBBL-NHCYSSNCSA-N Arg-Gln-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O LMPKCSXZJSXBBL-NHCYSSNCSA-N 0.000 description 2
• LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 2
• 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 2
• 108050006947 CXC Chemokine Proteins 0.000 description 2
• 102000019388 CXC chemokine Human genes 0.000 description 2
• 101100135641 Caenorhabditis elegans par-3 gene Proteins 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 208000014882 Carotid artery disease Diseases 0.000 description 2
• 208000002177 Cataract Diseases 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• NOCCABSVTRONIN-CIUDSAMLSA-N Cys-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N NOCCABSVTRONIN-CIUDSAMLSA-N 0.000 description 2
• 206010058202 Cystoid macular oedema Diseases 0.000 description 2
• 108020005199 Dehydrogenases Proteins 0.000 description 2
• 239000004375 Dextrin Substances 0.000 description 2
• 229920001353 Dextrin Polymers 0.000 description 2
• 206010012692 Diabetic uveitis Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 208000001351 Epiretinal Membrane Diseases 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• GURIQZQSTBBHRV-SRVKXCTJSA-N Gln-Lys-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GURIQZQSTBBHRV-SRVKXCTJSA-N 0.000 description 2
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
• 208000002927 Hamartoma Diseases 0.000 description 2
• VLDVBZICYBVQHB-IUCAKERBSA-N His-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CN=CN1 VLDVBZICYBVQHB-IUCAKERBSA-N 0.000 description 2
• 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 2
• 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
• NGKPIPCGMLWHBX-WZLNRYEVSA-N Ile-Tyr-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NGKPIPCGMLWHBX-WZLNRYEVSA-N 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 2
• XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
• 108060004795 Methyltransferase Proteins 0.000 description 2
• 208000009857 Microaneurysm Diseases 0.000 description 2
• 101000617124 Mus musculus Stromal cell-derived factor 1 Proteins 0.000 description 2
• BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
• 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 229920002413 Polyhexanide Polymers 0.000 description 2
• 229920001710 Polyorthoester Polymers 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 2
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 201000007527 Retinal artery occlusion Diseases 0.000 description 2
• 201000000582 Retinoblastoma Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
• 206010038934 Retinopathy proliferative Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 229920002125 Sokalan® Polymers 0.000 description 2
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 231100000480 WST assay Toxicity 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
• 229960004373 acetylcholine Drugs 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 238000006065 biodegradation reaction Methods 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 229940105329 carboxymethylcellulose Drugs 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 230000001332 colony forming effect Effects 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 239000000599 controlled substance Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 201000010206 cystoid macular edema Diseases 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 235000019425 dextrin Nutrition 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 208000024519 eye neoplasm Diseases 0.000 description 2
• 210000000744 eyelid Anatomy 0.000 description 2
• 230000004438 eyesight Effects 0.000 description 2
• 210000004700 fetal blood Anatomy 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 108010050848 glycylleucine Proteins 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 102000034345 heterotrimeric G proteins Human genes 0.000 description 2
• 108091006093 heterotrimeric G proteins Proteins 0.000 description 2
• 102000043525 human CXCL12 Human genes 0.000 description 2
• 230000003301 hydrolyzing effect Effects 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 108010034529 leucyl-lysine Proteins 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000002438 mitochondrial effect Effects 0.000 description 2
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 230000030691 negative chemotaxis Effects 0.000 description 2
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 238000002515 oligonucleotide synthesis Methods 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 230000000649 photocoagulation Effects 0.000 description 2
• 238000002428 photodynamic therapy Methods 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
• 239000004632 polycaprolactone Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920002689 polyvinyl acetate Polymers 0.000 description 2
• 239000011118 polyvinyl acetate Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 230000030786 positive chemotaxis Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000003938 response to stress Effects 0.000 description 2
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
• 210000001957 retinal vein Anatomy 0.000 description 2
• 108700004121 sarkosyl Proteins 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229940126585 therapeutic drug Drugs 0.000 description 2
• ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 230000000472 traumatic effect Effects 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 230000001982 uveitic effect Effects 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 230000004393 visual impairment Effects 0.000 description 2
• 239000002699 waste material Substances 0.000 description 2
• VSJZWDXZUNQTBO-BOMBAVFCSA-N (2s)-2-amino-n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]-4-hydroxybutanamide Chemical compound OCC[C@H](N)C(=O)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCCCC1 VSJZWDXZUNQTBO-BOMBAVFCSA-N 0.000 description 1
• RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 1
• HQGRTAMXYWZZOR-JNLGVIEDSA-N (2s)-n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]piperidine-2-carboxamide Chemical compound O=C([C@H]1NCCCC1)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCCCC1 HQGRTAMXYWZZOR-JNLGVIEDSA-N 0.000 description 1
• SDFYFIRUYZGZPG-GMUMFXLYSA-N (3r)-n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]piperidine-3-carboxamide Chemical compound O=C([C@H]1CNCCC1)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCCCC1 SDFYFIRUYZGZPG-GMUMFXLYSA-N 0.000 description 1
• VMVKHCSARBZILS-PBGLPUTKSA-N (3r)-n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]pyrrolidine-3-carboxamide Chemical compound O=C([C@H]1CNCC1)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCCN1C1CCCCC1 VMVKHCSARBZILS-PBGLPUTKSA-N 0.000 description 1
• QUPFKBITVLIQNA-KPKJPENVSA-N (5e)-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=CC(C=2OC(\C=C\3C(NC(=S)S/3)=O)=CC=2)=C1 QUPFKBITVLIQNA-KPKJPENVSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
• CZSXIGLHRRJGPZ-UHFFFAOYSA-N 1-oxothian-4-one Chemical compound O=C1CCS(=O)CC1 CZSXIGLHRRJGPZ-UHFFFAOYSA-N 0.000 description 1
• NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
• OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 1
• MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
• WELHCKCHZYENBT-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)propanamide Chemical compound NC(=O)CCC1=CN=CN1 WELHCKCHZYENBT-UHFFFAOYSA-N 0.000 description 1
• SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
• CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
• 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
• 101100309761 Aedes aegypti SDR-1 gene Proteins 0.000 description 1
• MBWYUTNBYSSUIQ-HERUPUMHSA-N Ala-Asn-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N MBWYUTNBYSSUIQ-HERUPUMHSA-N 0.000 description 1
• XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010002945 Aphakia Diseases 0.000 description 1
• 102100029470 Apolipoprotein E Human genes 0.000 description 1
• 101710095339 Apolipoprotein E Proteins 0.000 description 1
• PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
• XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 1
• WYBVBIHNJWOLCJ-IUCAKERBSA-N Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N WYBVBIHNJWOLCJ-IUCAKERBSA-N 0.000 description 1
• BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
• WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 1
• UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
• 238000012371 Aseptic Filling Methods 0.000 description 1
• TZFQICWZWFNIKU-KKUMJFAQSA-N Asn-Leu-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 TZFQICWZWFNIKU-KKUMJFAQSA-N 0.000 description 1
• RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 1
• HZZIFFOVHLWGCS-KKUMJFAQSA-N Asn-Phe-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O HZZIFFOVHLWGCS-KKUMJFAQSA-N 0.000 description 1
• MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
• ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
• RYEWQKQXRJCHIO-SRVKXCTJSA-N Asp-Asn-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RYEWQKQXRJCHIO-SRVKXCTJSA-N 0.000 description 1
• JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 1
• WNGZKSVJFDZICU-XIRDDKMYSA-N Asp-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N WNGZKSVJFDZICU-XIRDDKMYSA-N 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 241000726103 Atta Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
• 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
• 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
• 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
• 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 101150066398 CXCR4 gene Proteins 0.000 description 1
• 101100489581 Caenorhabditis elegans par-5 gene Proteins 0.000 description 1
• 101100407060 Caenorhabditis elegans par-6 gene Proteins 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 239000004155 Chlorine dioxide Substances 0.000 description 1
• 208000033379 Chorioretinopathy Diseases 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108010077840 Complement C3a Proteins 0.000 description 1
• 108010078546 Complement C5a Proteins 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010011017 Corneal graft rejection Diseases 0.000 description 1
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
• 101710095468 Cyclase Proteins 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• CUXIOFHFFXNUGG-HTFCKZLJSA-N Cys-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CS)N CUXIOFHFFXNUGG-HTFCKZLJSA-N 0.000 description 1
• SSNJZBGOMNLSLA-CIUDSAMLSA-N Cys-Leu-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O SSNJZBGOMNLSLA-CIUDSAMLSA-N 0.000 description 1
• OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 1
• MSWBLPLBSLQVME-XIRDDKMYSA-N Cys-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CS)=CNC2=C1 MSWBLPLBSLQVME-XIRDDKMYSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• 229930182843 D-Lactic acid Natural products 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 208000029728 Eyelid disease Diseases 0.000 description 1
• 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 208000008069 Geographic Atrophy Diseases 0.000 description 1
• JZOYFBPIEHCDFV-YUMQZZPRSA-N Gln-His Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 JZOYFBPIEHCDFV-YUMQZZPRSA-N 0.000 description 1
• LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 1
• VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
• SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
• UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
• GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 1
• QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 1
• XXGQRGQPGFYECI-WDSKDSINSA-N Gly-Cys-Glu Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCC(O)=O XXGQRGQPGFYECI-WDSKDSINSA-N 0.000 description 1
• COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
• DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
• VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• RNMNYMDTESKEAJ-KKUMJFAQSA-N His-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 RNMNYMDTESKEAJ-KKUMJFAQSA-N 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 201000002563 Histoplasmosis Diseases 0.000 description 1
• 101000798902 Homo sapiens Atypical chemokine receptor 4 Proteins 0.000 description 1
• 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
• 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
• 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
• 101001061807 Homo sapiens Rab-like protein 6 Proteins 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• WKXVAXOSIPTXEC-HAFWLYHUSA-N Ile-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O WKXVAXOSIPTXEC-HAFWLYHUSA-N 0.000 description 1
• MQFGXJNSUJTXDT-QSFUFRPTSA-N Ile-Gly-Ile Chemical compound N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)O MQFGXJNSUJTXDT-QSFUFRPTSA-N 0.000 description 1
• GAZGFPOZOLEYAJ-YTFOTSKYSA-N Ile-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N GAZGFPOZOLEYAJ-YTFOTSKYSA-N 0.000 description 1
• PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 1
• OWSWUWDMSNXTNE-GMOBBJLQSA-N Ile-Pro-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N OWSWUWDMSNXTNE-GMOBBJLQSA-N 0.000 description 1
• COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
• 206010023230 Joint stiffness Diseases 0.000 description 1
• PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
• TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
• XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 description 1
• MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
• WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 1
• RSFGIMMPWAXNML-MNXVOIDGSA-N Leu-Gln-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RSFGIMMPWAXNML-MNXVOIDGSA-N 0.000 description 1
• HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
• LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
• UBZGNBKMIJHOHL-BZSNNMDCSA-N Leu-Leu-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 UBZGNBKMIJHOHL-BZSNNMDCSA-N 0.000 description 1
• IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
• XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 1
• ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 102100035304 Lymphotactin Human genes 0.000 description 1
• SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 1
• UETQMSASAVBGJY-QWRGUYRKSA-N Lys-Gly-His Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 UETQMSASAVBGJY-QWRGUYRKSA-N 0.000 description 1
• NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
• OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 1
• FMIIKPHLJKUXGE-GUBZILKMSA-N Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN FMIIKPHLJKUXGE-GUBZILKMSA-N 0.000 description 1
• IVFUVMSKSFSFBT-NHCYSSNCSA-N Lys-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN IVFUVMSKSFSFBT-NHCYSSNCSA-N 0.000 description 1
• KEPWSUPUFAPBRF-DKIMLUQUSA-N Lys-Ile-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KEPWSUPUFAPBRF-DKIMLUQUSA-N 0.000 description 1
• OVAOHZIOUBEQCJ-IHRRRGAJSA-N Lys-Leu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OVAOHZIOUBEQCJ-IHRRRGAJSA-N 0.000 description 1
• AZOFEHCPMBRNFD-BZSNNMDCSA-N Lys-Phe-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 AZOFEHCPMBRNFD-BZSNNMDCSA-N 0.000 description 1
• ZVZRQKJOQQAFCF-ULQDDVLXSA-N Lys-Tyr-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZVZRQKJOQQAFCF-ULQDDVLXSA-N 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• 208000031471 Macular fibrosis Diseases 0.000 description 1
• 206010025421 Macule Diseases 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
• YORIKIDJCPKBON-YUMQZZPRSA-N Met-Glu-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YORIKIDJCPKBON-YUMQZZPRSA-N 0.000 description 1
• QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 1
• WPTHAGXMYDRPFD-SRVKXCTJSA-N Met-Lys-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O WPTHAGXMYDRPFD-SRVKXCTJSA-N 0.000 description 1
• KYXDADPHSNFWQX-VEVYYDQMSA-N Met-Thr-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O KYXDADPHSNFWQX-VEVYYDQMSA-N 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
• 241000713869 Moloney murine leukemia virus Species 0.000 description 1
• 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 1
• 101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 description 1
• 101100170937 Mus musculus Dnmt1 gene Proteins 0.000 description 1
• 101100460844 Mus musculus Nr2f6 gene Proteins 0.000 description 1
• 101001073421 Mus musculus Pigment epithelium-derived factor Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
• XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
• 108010049175 N-substituted Glycines Proteins 0.000 description 1
• 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
• 206010056677 Nerve degeneration Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 102100038434 Neuroplastin Human genes 0.000 description 1
• 108700038050 Neuroplastin Proteins 0.000 description 1
• 206010029333 Neurosis Diseases 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
• 206010065700 Ocular sarcoidosis Diseases 0.000 description 1
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 description 1
• 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 206010065373 Papillophlebitis Diseases 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• 101150003479 Parg gene Proteins 0.000 description 1
• 208000004788 Pars Planitis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091093037 Peptide nucleic acid Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• GDBOREPXIRKSEQ-FHWLQOOXSA-N Phe-Gln-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GDBOREPXIRKSEQ-FHWLQOOXSA-N 0.000 description 1
• FMMIYCMOVGXZIP-AVGNSLFASA-N Phe-Glu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O FMMIYCMOVGXZIP-AVGNSLFASA-N 0.000 description 1
• HQCSLJFGZYOXHW-KKUMJFAQSA-N Phe-His-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)O)N HQCSLJFGZYOXHW-KKUMJFAQSA-N 0.000 description 1
• JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
• DVOCGBNHAUHKHJ-DKIMLUQUSA-N Phe-Ile-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O DVOCGBNHAUHKHJ-DKIMLUQUSA-N 0.000 description 1
• BWTKUQPNOMMKMA-FIRPJDEBSA-N Phe-Ile-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BWTKUQPNOMMKMA-FIRPJDEBSA-N 0.000 description 1
• CMHTUJQZQXFNTQ-OEAJRASXSA-N Phe-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O CMHTUJQZQXFNTQ-OEAJRASXSA-N 0.000 description 1
• GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 108010003541 Platelet Activating Factor Proteins 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000148 Polycarbophil calcium Polymers 0.000 description 1
• 208000003971 Posterior uveitis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ZBAGOWGNNAXMOY-IHRRRGAJSA-N Pro-Cys-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZBAGOWGNNAXMOY-IHRRRGAJSA-N 0.000 description 1
• VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 1
• CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 1
• 108010026552 Proteome Proteins 0.000 description 1
• 208000033796 Pseudophakia Diseases 0.000 description 1
• 206010037649 Pyogenic granuloma Diseases 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 102100029618 Rab-like protein 6 Human genes 0.000 description 1
• 206010064714 Radiation retinopathy Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
• 102100040756 Rhodopsin Human genes 0.000 description 1
• 108090000820 Rhodopsin Proteins 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 102000003800 Selectins Human genes 0.000 description 1
• 108090000184 Selectins Proteins 0.000 description 1
• WKLJLEXEENIYQE-SRVKXCTJSA-N Ser-Cys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WKLJLEXEENIYQE-SRVKXCTJSA-N 0.000 description 1
• WOJYIMBIKTWKJO-KKUMJFAQSA-N Ser-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CO)N WOJYIMBIKTWKJO-KKUMJFAQSA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 229920002385 Sodium hyaluronate Polymers 0.000 description 1
• 208000004350 Strabismus Diseases 0.000 description 1
• 208000036038 Subretinal fibrosis Diseases 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• UQTNIFUCMBFWEJ-IWGUZYHVSA-N Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O UQTNIFUCMBFWEJ-IWGUZYHVSA-N 0.000 description 1
• BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 description 1
• UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 1
• FKIGTIXHSRNKJU-IXOXFDKPSA-N Thr-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CN=CN1 FKIGTIXHSRNKJU-IXOXFDKPSA-N 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 241000390203 Trachoma Species 0.000 description 1
• RRXPAFGTFQIEMD-IVJVFBROSA-N Trp-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N RRXPAFGTFQIEMD-IVJVFBROSA-N 0.000 description 1
• XGEUYEOEZYFHRL-KKXDTOCCSA-N Tyr-Ala-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 XGEUYEOEZYFHRL-KKXDTOCCSA-N 0.000 description 1
• WZQZUVWEPMGIMM-JYJNAYRXSA-N Tyr-Gln-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O WZQZUVWEPMGIMM-JYJNAYRXSA-N 0.000 description 1
• JJNXZIPLIXIGBX-HJPIBITLSA-N Tyr-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JJNXZIPLIXIGBX-HJPIBITLSA-N 0.000 description 1
• OKDNSNWJEXAMSU-IRXDYDNUSA-N Tyr-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 OKDNSNWJEXAMSU-IRXDYDNUSA-N 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 1
• DAVNYIUELQBTAP-XUXIUFHCSA-N Val-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DAVNYIUELQBTAP-XUXIUFHCSA-N 0.000 description 1
• 208000036866 Vitreoretinopathy Diseases 0.000 description 1
• 108010031318 Vitronectin Proteins 0.000 description 1
• 102100035140 Vitronectin Human genes 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
• KITLPLLNIZOYIJ-UUOKFMHZSA-N [[(2r,3s,4r,5r)-5-(2-amino-6-oxo-7,8-dihydro-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2NCN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O KITLPLLNIZOYIJ-UUOKFMHZSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000004308 accommodation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
• 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
• WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 108010008355 arginyl-glutamine Proteins 0.000 description 1
• 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
• 108010092854 aspartyllysine Proteins 0.000 description 1
• 238000011948 assay development Methods 0.000 description 1
• 201000009310 astigmatism Diseases 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 201000007917 background diabetic retinopathy Diseases 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 210000002960 bfu-e Anatomy 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 206010005159 blepharospasm Diseases 0.000 description 1
• 230000000744 blepharospasm Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 208000015294 blood coagulation disease Diseases 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 229960003679 brimonidine Drugs 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• NLAMRLZPVVKXTK-UHFFFAOYSA-N but-1-enyl acetate Chemical class CCC=COC(C)=O NLAMRLZPVVKXTK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 235000010410 calcium alginate Nutrition 0.000 description 1
• 239000000648 calcium alginate Substances 0.000 description 1
• 229960002681 calcium alginate Drugs 0.000 description 1
• OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001733 carboxylic acid esters Chemical class 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 201000005849 central retinal artery occlusion Diseases 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 229940045110 chitosan Drugs 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 235000019398 chlorine dioxide Nutrition 0.000 description 1
• QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
• 210000004240 ciliary body Anatomy 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 208000021921 corneal disease Diseases 0.000 description 1
• 201000007717 corneal ulcer Diseases 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 108010004073 cysteinylcysteine Proteins 0.000 description 1
• 229940022769 d- lactic acid Drugs 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 208000011325 dry age related macular degeneration Diseases 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000008497 endothelial barrier function Effects 0.000 description 1
• 210000000267 erythroid cell Anatomy 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 238000009207 exercise therapy Methods 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 1
• 108010015792 glycyllysine Proteins 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• GCWKPPGPWZXRJG-UHFFFAOYSA-N guanidine;phosphoric acid Chemical compound NC(N)=N.OP(O)(O)=O.OP(O)(O)=O GCWKPPGPWZXRJG-UHFFFAOYSA-N 0.000 description 1
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
• 229940029575 guanosine Drugs 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 208000034737 hemoglobinopathy Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 231100000753 hepatic injury Toxicity 0.000 description 1
• 229960004867 hexetidine Drugs 0.000 description 1
• 108010025306 histidylleucine Proteins 0.000 description 1
• 102000055647 human CSF2RB Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 239000010800 human waste Substances 0.000 description 1
• 150000001261 hydroxy acids Chemical class 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
• 230000037451 immune surveillance Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000010468 interferon response Effects 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
• 108010078274 isoleucylvaline Proteins 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229940116871 l-lactate Drugs 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 238000013532 laser treatment Methods 0.000 description 1
• 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 1
• 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 1
• 108010012058 leucyltyrosine Proteins 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 150000002634 lipophilic molecules Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 208000019420 lymphoid neoplasm Diseases 0.000 description 1
• 108010019677 lymphotactin Proteins 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 108010053062 lysyl-arginyl-phenylalanyl-lysine Proteins 0.000 description 1
• 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
• 108010064235 lysylglycine Proteins 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
• 229960004329 metformin hydrochloride Drugs 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 108010005942 methionylglycine Proteins 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000003551 muscarinic effect Effects 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• ZKZWNYUCHLGVKF-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]-1-ethylpiperidine-4-carboxamide Chemical compound C1CN(CC)CCC1C(=O)NCCC1N(C2CCCCC2)CCCC1NC1=NC=CC(N2CCCCCC2)=N1 ZKZWNYUCHLGVKF-UHFFFAOYSA-N 0.000 description 1
• BDDIRWMLJIEXOE-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpiperidin-2-yl]ethyl]-n-(oxan-4-yl)piperidine-4-carboxamide Chemical compound N=1C=CC(N2CCCCCC2)=NC=1NC1CCCN(C2CCCCC2)C1CCN(C1CCOCC1)C(=O)C1CCNCC1 BDDIRWMLJIEXOE-UHFFFAOYSA-N 0.000 description 1
• JXZWSVUUKPQGQK-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-cyclohexylpyrrolidin-2-yl]ethyl]morpholine-2-carboxamide Chemical compound C1NCCOC1C(=O)NCCC1C(NC=2N=C(C=CN=2)N2CCCCCC2)CCN1C1CCCCC1 JXZWSVUUKPQGQK-UHFFFAOYSA-N 0.000 description 1
• UWYZNDFRDXEQHY-UHFFFAOYSA-N n-[2-[3-[[4-(azepan-1-yl)pyrimidin-2-yl]amino]-1-propan-2-ylpiperidin-2-yl]ethyl]-1-ethylpiperidine-4-carboxamide Chemical compound C1CN(CC)CCC1C(=O)NCCC1N(C(C)C)CCCC1NC1=NC=CC(N2CCCCCC2)=N1 UWYZNDFRDXEQHY-UHFFFAOYSA-N 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 208000015238 neurotic disease Diseases 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 108091008104 nucleic acid aptamers Proteins 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 229940023490 ophthalmic product Drugs 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 150000002905 orthoesters Chemical class 0.000 description 1
• 238000002751 oxidative stress assay Methods 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 101150093826 par1 gene Proteins 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000035778 pathophysiological process Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
• 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229960002169 plerixafor Drugs 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920002492 poly(sulfone) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229950005134 polycarbophil Drugs 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920002959 polymer blend Polymers 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 201000004849 posterior scleritis Diseases 0.000 description 1
• 201000002267 posterior uveal melanoma Diseases 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 201000010041 presbyopia Diseases 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 150000003147 proline derivatives Chemical class 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 108010079317 prolyl-tyrosine Proteins 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 208000022749 pupil disease Diseases 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 208000014733 refractive error Diseases 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000004263 retinal angiogenesis Effects 0.000 description 1
• 210000001927 retinal artery Anatomy 0.000 description 1
• 230000004258 retinal degeneration Effects 0.000 description 1
• 230000004283 retinal dysfunction Effects 0.000 description 1
• 239000000790 retinal pigment Substances 0.000 description 1
• 210000001210 retinal vessel Anatomy 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 230000008684 selective degradation Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 230000003584 silencer Effects 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 239000012798 spherical particle Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 230000009221 stress response pathway Effects 0.000 description 1
• 210000003537 structural cell Anatomy 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 108010061238 threonyl-glycine Proteins 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 206010044325 trachoma Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 108010044292 tryptophyltyrosine Proteins 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000003074 vasoproliferative effect Effects 0.000 description 1
• 208000020854 vein disease Diseases 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000007966 viscous suspension Substances 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 229920003176 water-insoluble polymer Polymers 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1